bevacizumab + trastuzumab + vinorelbine

The combination of bevacizumab, trastuzumab, and vinorelbine is a treatment regimen used primarily for HER2-positive metastatic breast cancer. This combination brings together three distinct medications, each with its own mechanism of action. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF-A), inhibiting angiogenesis and thereby reducing blood vessel formation that supports tumor growth[7]. Trastuzumab is a monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor protein (HER2), suppressing cancer cell growth, proliferation, and survival[4]. Vinorelbine is an anti-mitotic chemotherapy drug that disrupts microtubule assembly, preventing cell division[6]. Clinical studies have evaluated this triple combination for HER2-positive metastatic breast cancer. A Phase II study aimed to assess both the efficacy and feasibility of combining these three agents[1][5]. While the combination showed notable activity in HER2-positive metastatic breast cancer, researchers observed unacceptable toxicity rates that were higher than previously reported with vinorelbine/trastuzumab or vinorelbine/bevacizumab doublet combinations[1]. The treatment regimen typically involves bevacizumab administered intravenously every 2 weeks, while trastuzumab and vinorelbine are given intravenously once a week[2]. Some studies have explored metronomic (low-dose, frequent) administration of vinorelbine in combination with these targeted therapies to potentially reduce side effects while maintaining efficacy[9][10]. For HER2-positive metastatic breast cancer, this combination represents one of several treatment options. While the trastuzumab/vinorelbine doublet has been established as an effective and well-tolerated first-line treatment for HER2-positive metastatic breast cancer[8], the addition of bevacizumab appears to increase toxicity without providing sufficient additional benefit to justify its routine use in this triple combination[1][3].